atazanavir has been researched along with darunavir in 30 studies
| Studies (atazanavir) | Trials (atazanavir) | Recent Studies (post-2010) (atazanavir) | Studies (darunavir) | Trials (darunavir) | Recent Studies (post-2010) (darunavir) |
|---|---|---|---|---|---|
| 75 | 1 | 37 | 1,148 | 224 | 780 |
| Protein | Taxonomy | atazanavir (IC50) | darunavir (IC50) |
|---|---|---|---|
| Chain A, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| Chain B, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| Chain A, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| Chain B, HIV-1 protease | Human immunodeficiency virus 1 | 0.0028 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 6.6 | |
| Protease | Human immunodeficiency virus 1 | 0.063 | |
| Protease | Human immunodeficiency virus 1 | 0.0014 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 16 (53.33) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Azijn, H; de Bethune, MP; de Kock, HA; De Meyer, S; King, NM; Maes, LJ; Pauwels, R; Peeters, A; Pille, GM; Prabu-Jeyabalan, M; Schiffer, CA; Surleraux, DL; Vendeville, S; Verschueren, WG; Wigerinck, PB | 1 |
| Andrews, CW; Brieger, M; Furfine, ES; Hale, MR; Hanlon, MH; Hazen, RJ; Kaldor, I; McLean, EW; Miller, JF; Reynolds, D; Sammond, DM; Sherrill, RG; Spaltenstein, A; Tung, R; Turner, EM; Xu, RX | 1 |
| Amano, M; Boross, PI; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Li, J; Mitsuya, H; Wang, YF; Weber, IT | 1 |
| Bernstein, B; Dekhtyar, T; Gao, F; Hanna, GJ; Kempf, D; Koev, G; Lu, L; Lu, X; Masse, S; Mo, H; Molla, A | 1 |
| Boone, L; Craig, C; Ferris, R; Furfine, E; Griffin, P; Hale, M; Hanlon, M; Harvey, R; Hazen, R; Kaldor, I; Miller, J; Ray, J; Samano, V; Spaltenstein, A; St Clair, M; Tung, R; Yates, P | 1 |
| Babusis, D; Bhoopathy, S; Hidalgo, IJ; Phan, TK; Ray, AS; Rhodes, GR; Robinson, KL; Strab, R; Tong, L | 1 |
| DeGoey, DA; Dekhtyar, T; Flosi, WJ; Grampovnik, DJ; Kempf, DJ; Klein, LL; Lu, L; Masse, S; Molla, A; Ng, TI | 1 |
| Bénard, A; Brun-Vézinet, F; Campa, P; Chêne, G; Collin, G; Damond, F; Desbois, D; Descamps, D; Matheron, S; Peytavin, G; Roquebert, B | 1 |
| Brynda, J; Cígler, P; Fanfrlík, J; Grantz Sasková, K; Grüner, B; Konvalinka, J; Kozísek, M; Král, V; Lepsík, M; Plesek, J; Pokorná, J; Rezácová, P; Václavíková, J | 1 |
| Amano, M; Das, D; Ghosh, AK; Koh, Y; Leschenko, S; Mitsuya, H; Nakata, H; Nakayama, M; Ogata-Aoki, H | 1 |
| Chen, HJ; Colletti, L; Degoey, DA; Dekhtyar, T; Flentge, CA; Flosi, WJ; Grampovnik, DJ; Kati, WM; Kempf, DJ; Klein, LL; Mamo, M; Marsh, KC; Mo, H; Molla, A; Morfitt, DC; Nguyen, B; Randolph, JT; Schmidt, JM; Stoll, V; Swanson, SJ; Yeung, CM | 1 |
| Axelsson, L; Ekegren, JK; Hallberg, A; Kihlström, J; Larhed, M; Mahalingam, AK; Samuelsson, B; Unge, T; Wallberg, H; Wannberg, J | 1 |
| Amano, M; Baldridge, A; Gemma, S; Ghosh, AK; Ide, K; Koh, Y; Mitsuya, H; Simoni, E; Tojo, Y; Walters, DE | 1 |
| Amano, M; Anderson, DD; Aoki, M; Das, D; Ghosh, AK; Koh, Y; Kulkarni, S; Mitsuya, H; Tojo, Y | 1 |
| Kempf, DJ; Norton, M; Parkin, NT; Pilot-Matias, T; Stawiski, E; Trinh, R; Young, TP | 1 |
| Cane, PA; Kolli, M; Myers, RE; Parry, CM; Pillay, D; Schiffer, C | 1 |
| Amano, M; Baldridge, A; Chapsal, BD; Ghosh, AK; Koh, Y; Mitsuya, H; Steffey, MP; Walters, DE | 1 |
| Hamburger, M; Hamy, F; Klimkait, T; Louvel, S; Mojarrab, M; Potterat, O; Sanglier, JJ; Vidal, V | 1 |
| Afonina, E; Eissenstat, M; Erickson, J; Guerassina, T; Gulnik, S; Ludtke, D; Silva, AM; Yokoe, H; Yu, B | 1 |
| Amssoms, K; Austin, N; Baert, L; Dierynck, I; Hache, G; Jönsson, D; Kalayanov, G; Kesteleyn, B; Lundgren, S; Masungi, C; Meurs, G; Parkes, K; Rombauts, K; Rosenquist, A; Samuelsson, B; Schepens, W; Sterkens, P; Stoops, B; Thuring, JW; Van De Vreken, W; Van Emelen, K; Verschueren, W; Wallberg, H; Wegner, J | 1 |
| Agniswamy, J; Ghosh, AK; Louis, JM; Rao, KV; Sayer, JM; Shen, CH; Wang, YF; Weber, IT; Xu, CX | 1 |
| Hohlfeld, K; Kesteleyn, B; Linclau, B; Tomassi, C; Wegner, JK | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Agniswamy, J; Aoki, M; Bulut, H; Das, D; Ghosh, AK; Hayashi, H; Martyr, CD; Mitsuya, H; Nyalapatla, PR; Osswald, HL; Rao, KV; Wang, YF; Weber, IT | 1 |
| Bahnck-Teets, C; Ballard, JE; Bennett, DJ; Bungard, CJ; Carroll, SS; Chang, L; Chu, XJ; Crespo, A; Diamond, TL; Dwyer, MP; Fay, JF; Holloway, MK; Hu, B; Ji, T; Keertikar, K; Loughran, HM; Manikowski, JJ; McCauley, JA; Miller, MD; Min, X; Morriello, GJ; Morris, W; Schulz, J; Stamford, AW; Su, HP; Waddell, ST; Williams, PD; Wiscount, CM; Zhong, B | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Brindisi, M; Ghosh, AK; Kovela, S; Mitsuya, H; Osswald, HL; R Nyalapatla, P; Rao, KV; Wang, YF; Weber, IT | 1 |
| Agniswamy, J; Ghosh, AK; Hattori, SI; Hayashi, H; Ho, RY; Mitsuya, H; Simpson, HM; Wang, YF; Weber, IT; Williams, JN | 1 |
| Agniswamy, J; Amano, M; Aoki, M; Ghosh, AK; Kovela, S; Mitsuya, H; Osswald, HL; Wang, YF; Weber, IT | 1 |
| Ghosh, AK; Grillo, A; Hattori, SI; Higashi-Kuwata, N; Johnson, ME; Kneller, DW; Kovela, S; Mitsuya, H; Raghavaiah, J; Wang, YF; Weber, IT | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
1 review(s) available for atazanavir and darunavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
29 other study(ies) available for atazanavir and darunavir
| Article | Year |
|---|---|
Design of HIV-1 protease inhibitors active on multidrug-resistant virus.
Topics: Animals; Benzoxazoles; Binding Sites; Calorimetry; Cell Line; Crystallography, X-Ray; Dogs; Drug Resistance, Multiple, Viral; Drug Stability; HIV Protease Inhibitors; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Rats; Rats, Wistar; Sulfonamides; Thermodynamics; Thiazoles | 2005 |
Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385.
Topics: HIV Protease Inhibitors; Molecular Structure; Sulfonamides | 2006 |
A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Topics: Amino Acid Sequence; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Sulfonamides; Urethane; Virus Replication | 2007 |
In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir.
Topics: Amino Acid Sequence; Anti-HIV Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Core Protein p24; HIV Protease Inhibitors; HIV-2; Humans; Lopinavir; Molecular Sequence Data; Mutagenesis, Site-Directed; Phenotype; Pyrimidinones; RNA-Directed DNA Polymerase; Virus Replication | 2007 |
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Topics: Algorithms; Anti-Retroviral Agents; Benzodioxoles; Blood Proteins; Carbamates; Cell Line; Drug Resistance, Viral; HeLa Cells; HIV Protease Inhibitors; HIV-1; Humans; Orosomucoid; Phenotype; Serum; Serum Albumin; Tyrosine | 2007 |
Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
Topics: Adenine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Chromatography, High Pressure Liquid; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Epithelium; HIV Protease Inhibitors; Humans; Hydrolysis; Indicators and Reagents; Intestinal Absorption; Mass Spectrometry; Organophosphonates; Subcellular Fractions; Tenofovir | 2007 |
Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742.
Topics: Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Mutation; Phenotype; Pyrimidinones; Selection, Genetic; Serial Passage | 2008 |
In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.
Topics: Darunavir; HIV Protease; HIV Protease Inhibitors; HIV-2; Humans; Inhibitory Concentration 50; Lopinavir; Microbial Sensitivity Tests; Phenotype; Pyrimidinones; Saquinavir; Sulfonamides | 2008 |
Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Topics: Boron Compounds; Crystallography, X-Ray; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Metals; Models, Molecular; Molecular Structure; Mutation | 2008 |
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Topics: Amino Acid Sequence; Carbamates; Cyclopentanes; Dose-Response Relationship, Drug; Drug Resistance, Viral; Furans; HIV Protease Inhibitors; HIV-1; Humans; Inhibitory Concentration 50; Models, Molecular; Molecular Sequence Data; Molecular Structure; Sulfonamides | 2009 |
2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.
Topics: Animals; Binding Sites; Biological Availability; Caco-2 Cells; Carbamates; Cell Membrane Permeability; Crystallography, X-Ray; Dipeptides; Dogs; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Hyperlipidemias; In Vitro Techniques; Microsomes, Liver; Models, Molecular; Mutation; Putrescine; Pyridines; Rats; Rats, Gunn; Stereoisomerism; Structure-Activity Relationship | 2009 |
HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Topics: Alcohols; Antiviral Agents; Crystallography, X-Ray; HIV Protease; HIV Protease Inhibitors; HIV-1; Inhibitory Concentration 50; Molecular Mimicry; Mutation, Missense | 2010 |
Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.
Topics: Animals; Cricetinae; Crystallography, X-Ray; Drug Evaluation, Preclinical; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Ligands; Phenylbutyrates; Protein Binding; Stereoisomerism | 2010 |
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Topics: Cell Line; Dimerization; Drug Resistance, Multiple, Viral; Furans; Genetic Variation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Macrocyclic Compounds; Microbial Sensitivity Tests; Models, Molecular; Structure-Activity Relationship; Virus Replication | 2010 |
Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.
Topics: Antiviral Agents; Carbamates; Darunavir; Furans; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Mutation; Pyrimidinones; Sulfonamides | 2010 |
Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
Topics: Cell Line; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; gag Gene Products, Human Immunodeficiency Virus; HIV Antigens; HIV Protease Inhibitors; HIV-1; Humans; Mutagenesis, Site-Directed; Virus Replication | 2011 |
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.
Topics: Carbamates; Catalytic Domain; Cell Line; Crystallography, X-Ray; Drug Resistance, Multiple, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Protein Binding; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2011 |
Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Daphne; Diterpenes; Heterocyclic Compounds, 4 or More Rings; Mediterranean Region; Molecular Structure; Receptors, CXCR4 | 2012 |
Enamino-oxindole HIV protease inhibitors.
Topics: Binding Sites; Crystallography, X-Ray; Darunavir; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indoles; Oxindoles; Protein Structure, Tertiary; Structure-Activity Relationship; Sulfonamides | 2012 |
Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application.
Topics: Alkylation; Animals; Carbamates; Dipeptides; Drug Design; Half-Life; Halogenation; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microsomes, Liver; Pyridines; Rats; Structure-Activity Relationship | 2013 |
Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
Topics: Binding Sites; Calorimetry, Differential Scanning; Carbamates; Crystallization; Darunavir; Drug Resistance, Multiple; Drug Resistance, Viral; Escherichia coli; Furans; Genes, Synthetic; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Models, Molecular; Mutation; Pyrrolidinones; Structure-Activity Relationship; Sulfonamides | 2013 |
Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors.
Topics: | 2011 |
Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants.
Topics: Benzothiazoles; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple, Viral; Furans; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Molecular Docking Simulation; Pyrans; Structure-Activity Relationship; Sulfonamides | 2017 |
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.
Topics: | 2017 |
Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
Topics: Catalytic Domain; Crystallography, X-Ray; Drug Design; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Ligands; Models, Molecular; Molecular Structure; Protein Conformation; Stereoisomerism; Structure-Activity Relationship | 2018 |
Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.
Topics: Catalytic Domain; Chemistry Techniques, Synthetic; Drug Design; HIV Protease; HIV Protease Inhibitors; HIV-1; Ligands; Models, Molecular; Oxazolidinones; Stereoisomerism; Structure-Activity Relationship | 2018 |
Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
Topics: Amino Acid Substitution; Catalytic Domain; Cell Line, Tumor; Crystallography, X-Ray; Drug Design; Furans; Heterocyclic Compounds, Bridged-Ring; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Protein Binding; Stereoisomerism | 2020 |
Design, Synthesis, and X-ray Studies of Potent HIV-1 Protease Inhibitors with P2-Carboxamide Functionalities.
Topics: | 2020 |
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |